Therapeutic Insights on Ferroptosis in Parkinson's disease

Thapa, Komal; Khan, Heena; Kanojia, Neha; Singh, Thakur Gurjeet; Kaur, Amandeep; Kaur, Gagandeep

doi:10.1016/j.ejphar.2022.175133

Cited by 36 publications

(19 citation statements)

References 176 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NRF2 also regulates mitochondrial function and the expression of a variety of antioxidant genes. 46 After entering the nucleus, NRF2 binds to the antioxidant reaction element 11 (ARE11), which induces the expression of downstream antioxidant enzymes, such as GPX4 and superoxide dismutase (SOD) (Figure 3A). [47][48][49] Although the system xc − antiporter is the primary mechanism by which cells obtain cysteine, the transsulfuration pathway, which is dictated by the presence or absence of functional DJ-1, is a secondary mechanism.…”

Section: F I G U R Ementioning

confidence: 99%

“…Separately, in two randomized, double‐blind, placebo‐controlled phase II clinical trials, DFP reduced iron deposition in SN and progression of dyskinesia in early‐onset PD patients ( n = 19, NCT00943748; n = 22, NCT01539837) 91,92 . It should be noted that, low doses of DFP (15–30 mg/kg) were used in these clinical trials to prevent excess systemic iron chelation and associated adverse effects 46 . Moreover, DFP was the subject of two additional parallel‐group, placebo‐controlled, randomized phase II clinical trials focused on PD, the results of which are still pending ( n = 140, NCT02728843; n = 372, NCT02655315) 93,94 .…”

Section: Ferroptosis‐related Therapeutic Targets For Pdmentioning

confidence: 99%

See 1 more Smart Citation

Novel druggable mechanism of Parkinson's disease: Potential therapeutics and underlying pathogenesis based on ferroptosis

Jiang

et al. 2023

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

Section: F I G U R Ementioning

confidence: 99%

Section: Ferroptosis‐related Therapeutic Targets For Pdmentioning

confidence: 99%

Novel druggable mechanism of Parkinson's disease: Potential therapeutics and underlying pathogenesis based on ferroptosis

Jiang

et al. 2023

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…Alterations in iron homeostasis promote the pathophysiological effects observed in several neurodegenerative diseases [ 106 , 107 , 108 ]. Furthermore, the occurrence of ferroptosis as a type of recent cell death has been receiving increased attention given its apparent occurrence in neurodegenerative diseases and the positive effect of inhibitors of this process in the disease progression [ 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 ]. Targeting ferroptosis can thus be proposed as a potential new therapeutic target to stop/delay neurodegenerative disease progression.…”

Section: Neurodegenerative Diseasesmentioning

confidence: 99%

Intranasal Lipid Nanoparticles Containing Bioactive Compounds Obtained from Marine Sources to Manage Neurodegenerative Diseases

et al. 2023

View full text Add to dashboard Cite

Marine sources contain several bioactive compounds with high therapeutic potential, such as remarkable antioxidant activity that can reduce oxidative stress related to the pathogenesis of neurodegenerative diseases. Indeed, there has been a growing interest in these natural sources, especially those resulting from the processing of marine organisms (i.e., marine bio-waste), to obtain natural antioxidants as an alternative to synthetic antioxidants in a sustainable approach to promote circularity by recovering and creating value from these bio-wastes. However, despite their expected potential to prevent, delay, or treat neurodegenerative diseases, antioxidant compounds may have difficulty reaching the brain due to the need to cross the blood–brain barrier (BBB). In this regard, alternative delivery systems administered by different routes have been proposed, including intranasal administration of lipid nanoparticles, such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), which have shown promising results. Intranasal administration shows several advantages, including the fact that molecules do not need to cross the BBB to reach the central nervous system (CNS), as they can be transported directly from the nasal cavity to the brain (i.e., nose-to-brain transport). The benefits of using SLN and NLC for intranasal delivery of natural bioactive compounds for the treatment of neurodegenerative diseases have shown relevant outcomes through in vitro and in vivo studies. Noteworthy, for bioactive compounds obtained from marine bio-waste, few studies have been reported, showing the open potential of this research area. This review updates the state of the art of using SLN and NLC to transport bioactive compounds from different sources, in particular, those obtained from marine bio-waste, and their potential application in the treatment of neurodegenerative diseases.

show abstract

“…Recent approaches using intranasal DFO treatment attenuated synapse loss in the brains of AD model mice and inhibited Fe-induced APP cleavage [78,163]. DFO and other Fe chelators are focused on possible treatments for PD [164,165]. Moreover, clioquinol reportedly recovers the memory impairment in scrapie [166], and a Cu 2+ -specific chelator (D-(-)-penicillamine) reportedly inhibits the pathogenesis of prion diseases in vivo [167].…”

Section: Hypothesis: Cross-talk Occurs Between Trace Elements and Amy...mentioning

confidence: 99%

Dietary Trace Elements and the Pathogenesis of Neurodegenerative Diseases

2023

View full text Add to dashboard Cite

Trace elements such as iron (Fe), zinc (Zn), copper (Cu), and manganese (Mn) are absorbed from food via the gastrointestinal tract, transported into the brain, and play central roles in normal brain functions. An excess of these trace elements often produces reactive oxygen species and damages the brain. Moreover, increasing evidence suggests that the dyshomeostasis of these metals is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease, prion diseases, and Lewy body diseases. The disease-related amyloidogenic proteins can regulate metal homeostasis at the synapses, and thus loss of the protective functions of these amyloidogenic proteins causes neurodegeneration. Meanwhile, metal-induced conformational changes of the amyloidogenic proteins contribute to enhancing their neurotoxicity. Moreover, excess Zn and Cu play central roles in the pathogenesis of vascular-type senile dementia. Here, we present an overview of the intake, absorption, and transport of four essential elements (Fe, Zn, Cu, Mn) and one non-essential element (aluminum: Al) in food and their connections with the pathogenesis of neurodegenerative diseases based on metal–protein, and metal–metal cross-talk.

show abstract

Therapeutic Insights on Ferroptosis in Parkinson's disease

Cited by 36 publications

References 176 publications

Novel druggable mechanism of Parkinson's disease: Potential therapeutics and underlying pathogenesis based on ferroptosis

Novel druggable mechanism of Parkinson's disease: Potential therapeutics and underlying pathogenesis based on ferroptosis

Intranasal Lipid Nanoparticles Containing Bioactive Compounds Obtained from Marine Sources to Manage Neurodegenerative Diseases

Dietary Trace Elements and the Pathogenesis of Neurodegenerative Diseases

Contact Info

Product

Resources

About